Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab + Atezolizumab in Chemotherapy-Naïve Advanced NSCLC
NCT03563716Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 6
01
Overview
A Phase 2 trial of tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Started Aug 2018; status: completed.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03563716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563716.